In the SURMOUNT-4 trial, 100 patients with obesity were on tirezpatide for 9 months, and the average weight loss was 20.9 percent. The patients were then randomized to receive either placebo with behavioral intervention or tirzepatide for another year, and the patients in the former group regained a significant amount of weight. Dive further into the study’s findings and implications with Dr. John Buse and Dr. Louis Aronne, the Sanford I. Weill Professor of Metabolic Research at Weill Cornell Medical College in New York.
Dissecting Clinical Trial Data from the 81st Scientific Sessions
Diabetes & Dermatology: Uncovering Skin Conditions in Diabetic Patients
Investigating the Link Between Type 2 Diabetes & Obesity
Taking a New Approach to Treat Type 1 Diabetes
Improving Diabetes Care with Technology: A Look at Continuous Glucose Monitors
Discovering the Discordance Between Measured A1Cs & GMIs
Investigating SGLT-2 Inhibitors in Diabetes: Considerations & Conversation
A Wake-Up Call to Diabetes: Spreading Awareness of Its Seriousness
When & How to Screen Patients for Diabetes
Exploring Stem Cell Research & Novel Options in Type 1 Diabetes
Investigating Type 1 Diabetes & Its Chronic Impacts
Managing Diabetes During the COVID-19 Pandemic
Understanding Dapagliflozin: Examining Its Use in Chronic Kidney Disease
Assessing Atypical Diabetes: Detection & Diagnosis
Highlighting a Hero in Endocrinology: Dr. Jason Sloane
Fad Diets & Patients with Type 2 Diabetes
Cardio Considerations: Individualized Exercise for Patients with Type 2 Diabetes
Prescribing Exercise for Patients with Type 2 Diabetes
Dietary Decisions for Patients with Type 2 Diabetes
Difficulty with Diabetes: Strategies to Overcome Challenging Cases
Create your
podcast in
minutes
It is Free
RenaissanceOnlineRadio.com
Men in Lead Aprons
Denver Underground
Exercise: Learn To Love (Or At Least Like) It
NASACast Video